Literature DB >> 26091751

Association between non-fatal opioid overdose and encounters with healthcare and criminal justice systems: Identifying opportunities for intervention.

Karla D Wagner1, Lin Liu2, Peter J Davidson3, Jazmine Cuevas-Mota3, Richard F Armenta3, Richard S Garfein3.   

Abstract

BACKGROUND: Accidental overdose, driven largely by opioids, is a leading cause of death among people who inject drugs (PWIDs). We conducted secondary analysis of data from a cohort of PWIDs to identify venues where high-risk PWID could be targeted by overdose education/naloxone distribution (OEND) programs.
METHODS: 573 PWIDs completed a quantitative survey between June, 2012 and January, 2014, which was analyzed using multivariable logistic regression. The dependent variable was a dichotomous indicator of experiencing a heroin/opioid-related overdose in the past six months. Independent variables included: demographics, drug use behavior, and encounters with two venues - the health care and criminal justice systems - that could serve as potential venues for OEND programs.
RESULTS: Almost half (41.5%) reported ever experiencing a heroin/opioid overdose, and 45 (7.9%) reported experiencing at least one heroin/opioid overdose in the past six months. In the final multivariable model, receiving care in a hospital in the past six months (Adjusted Odds Ratio [AdjOR] 4.08, 95% Confidence Interval [C.I.] 2.07, 8.04, p<0.001) and being arrested for drug possession in the past six months (AdjOR 5.17, 95% C.I. 2.37, 11.24, p<0.001) were associated with experiencing an opioid overdose in the past six months.
CONCLUSIONS: Identifying venues outside of those that traditionally target services to PWIDs (i.e., syringe exchange programs) will be critical to implementing OEND interventions at a scale sufficient to address the growing epidemic of heroin/opioid related deaths. Clinical settings, such as hospitals, and drug-related encounters with law enforcement officers are promising venues for the expansion of OEND programs.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Naloxone; Opioids; Overdose; Overdose prevention; People who inject drugs

Mesh:

Substances:

Year:  2015        PMID: 26091751      PMCID: PMC4512661          DOI: 10.1016/j.drugalcdep.2015.05.026

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  42 in total

1.  Transition from first illicit drug use to first injection drug use among rural Appalachian drug users: a cross-sectional comparison and retrospective survival analysis.

Authors:  April M Young; Jennifer R Havens
Journal:  Addiction       Date:  2011-10-26       Impact factor: 6.526

2.  Intravenous use of illicit buprenorphine/naloxone to reverse an acute heroin overdose.

Authors:  Michael A Yokell; Nickolas D Zaller; Traci C Green; Michelle McKenzie; Josiah D Rich
Journal:  J Opioid Manag       Date:  2012 Jan-Feb

3.  The association between law enforcement encounters and syringe sharing among IDUs on skid row: a mixed methods analysis.

Authors:  Karla D Wagner; Rebecca Simon-Freeman; Ricky N Bluthenthal
Journal:  AIDS Behav       Date:  2013-10

4.  Police officers' and paramedics' experiences with overdose and their knowledge and opinions of Washington State's drug overdose-naloxone-Good Samaritan law.

Authors:  Caleb J Banta-Green; Leo Beletsky; Jennifer A Schoeppe; Phillip O Coffin; Patricia C Kuszler
Journal:  J Urban Health       Date:  2013-12       Impact factor: 3.671

5.  Non-fatal overdose and subsequent drug treatment among injection drug users.

Authors:  Robin A Pollini; Lisa McCall; Shruti H Mehta; David Vlahov; Steffanie A Strathdee
Journal:  Drug Alcohol Depend       Date:  2005-11-23       Impact factor: 4.492

6.  Social network correlates of self-reported non-fatal overdose.

Authors:  Carl A Latkin; Wei Hua; Karin Tobin
Journal:  Drug Alcohol Depend       Date:  2004-01-07       Impact factor: 4.492

7.  Overdose prevention and naloxone prescription for opioid users in San Francisco.

Authors:  Lauren Enteen; Joanna Bauer; Rachel McLean; Eliza Wheeler; Emalie Huriaux; Alex H Kral; Joshua D Bamberger
Journal:  J Urban Health       Date:  2010-12       Impact factor: 3.671

Review 8.  A systematic review of community opioid overdose prevention and naloxone distribution programs.

Authors:  Angela K Clark; Christine M Wilder; Erin L Winstanley
Journal:  J Addict Med       Date:  2014 May-Jun       Impact factor: 3.702

9.  Community-based opioid overdose prevention programs providing naloxone - United States, 2010.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2012-02-17       Impact factor: 17.586

10.  Problematic use of prescription-type opioids prior to heroin use among young heroin injectors.

Authors:  Robin A Pollini; Caleb J Banta-Green; Jazmine Cuevas-Mota; Mitcheal Metzner; Eyasu Teshale; Richard S Garfein
Journal:  Subst Abuse Rehabil       Date:  2011-10
View more
  16 in total

1.  Take-home naloxone possession among people who inject drugs in rural West Virginia.

Authors:  Sean T Allen; Rebecca Hamilton White; Allison O'Rourke; Suzanne M Grieb; Michael E Kilkenny; Susan G Sherman
Journal:  Drug Alcohol Depend       Date:  2019-09-21       Impact factor: 4.492

2.  Predictors of Overdose Death Among High-Risk Emergency Department Patients With Substance-Related Encounters: A Data Linkage Cohort Study.

Authors:  Noa Krawczyk; Matthew Eisenberg; Kristin E Schneider; Tom M Richards; B Casey Lyons; Kate Jackson; Lindsey Ferris; Jonathan P Weiner; Brendan Saloner
Journal:  Ann Emerg Med       Date:  2019-09-09       Impact factor: 5.721

3.  Differential experiences of Mexican policing by people who inject drugs residing in Tijuana and San Diego.

Authors:  Emily F Wood; Dan Werb; Leo Beletsky; Gudelia Rangel; Jazmine Cuevas Mota; Richard S Garfein; Steffanie A Strathdee; Karla D Wagner
Journal:  Int J Drug Policy       Date:  2017-01-19

4.  A randomized clinical trial of the effects of brief versus extended opioid overdose education on naloxone utilization outcomes by individuals with opioid use disorder.

Authors:  Jermaine D Jones; Aimee N Campbell; Laura Brandt; Verena E Metz; Suky Martinez; Melanie Wall; Thomas Corbeil; Howard Andrews; Felipe Castillo; Joanne Neale; John Strang; Stephen Ross; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2022-05-23       Impact factor: 4.852

5.  "I've been to more of my friends' funerals than I've been to my friends' weddings": Witnessing and responding to overdose in rural Northern New England.

Authors:  Kerry Nolte; Eric Romo; Thomas J Stopka; Aurora Drew; Patrick Dowd; Lizbeth Del Toro-Mejias; Elyse Bianchet; Peter D Friedmann
Journal:  J Rural Health       Date:  2022-03-17       Impact factor: 5.667

6.  Location of fatal prescription opioid-related deaths in 12 states, 2008-2010: Implications for prevention programs.

Authors:  Keith W Easterling; Karin A Mack; Christopher M Jones
Journal:  J Safety Res       Date:  2016-08-07

7.  Emotional reactions of trained overdose responders who use opioids following intervention in an overdose event.

Authors:  Laura Brandt; Aimee N C Campbell; Jermaine D Jones; Suky Martinez; Joanne Neale; Stephen Parkin; Caral Brown; John Strang; Sandra D Comer
Journal:  Subst Abus       Date:  2021-09-14       Impact factor: 3.716

8.  Association of Methadone Treatment With Substance-Related Hospital Admissions Among a Population in Canada With a History of Criminal Convictions.

Authors:  Angela Russolillo; Akm Moniruzzaman; Julian M Somers
Journal:  JAMA Netw Open       Date:  2019-03-01

9.  Changes in overdose knowledge and attitudes in an incarcerated sample of people living with HIV.

Authors:  Megan Reed; Anne Siegler; Loni P Tabb; Florence Momplaisir; Dorsche Krevitz; Stephen Lankenau
Journal:  Int J Prison Health       Date:  2021-06-15

10.  A scoping review of factors that influence opioid overdose prevention for justice-involved populations.

Authors:  Christine E Grella; Erika Ostlie; Christy K Scott; Michael L Dennis; John Carnevale; Dennis P Watson
Journal:  Subst Abuse Treat Prev Policy       Date:  2021-02-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.